Neoadjuvant chemotherapy enabling resection of stage IVA thymoma with myasthenia gravis and systemic lupus erythematosus: a case report - Top-Institutions - MDSpire

Neoadjuvant chemotherapy enabling resection of stage IVA thymoma with myasthenia gravis and systemic lupus erythematosus: a case report

By
Carlos A. Cedeno
Edgardo Santiago
Alex R. Cedeño
Jean Lafontaine
Maria J. Marcos
Omar Concepción
July 16, 2026

Frontiers In Oncology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

The University of Texas MD Anderson Cancer Center

Houston, Texas
Key Differentiators
- Oncology
- Thoracic Surgery
#2

Memorial Sloan Kettering Cancer Center

New York, New York
Key Differentiators
- Oncology
#3

Dana-Farber/Brigham and Women’s Hospital

Boston, Massachusetts
Key Differentiators
- Oncology
#4

Peking Union Medical College Hospital

Beijing, China
Key Differentiators
- Oncology
#5

Azienda Ospedaliero-Universitaria di Bologna

Bologna, Italy
Key Differentiators
- Oncology

Original Source(s)

Frontiers In Oncology

Neoadjuvant chemotherapy enabling resection of stage IVA thymoma with myasthenia gravis and systemic lupus erythematosus: a case report

by Carlos A. Cedeno, Edgardo Santiago, Alex R. Cedeño, Jean Lafontaine, Maria J. Marcos, Omar Concepción
July 16, 2026

Related Content

Frontiers In Immunology

Commentary: Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities

by Lidetian Hu, Haixing Cao, Yujie Zhang, Xiang Ma
July 15, 2026

Frontiers In Immunology

Immunological barriers and engineering strategies for CAR-T cell therapy in acute myeloid leukemia

by Ya Wang, Tiantian Yu, Ming Wang, Li Yu
July 15, 2026

Frontiers In Immunology

Gastrointestinal acute graft versus host disease: a translational perspective from pathogenesis to precision prevention and treatment

by Zhengwei Tan, Jinyu Hu, Baodong Ye, Wenbin Liu
July 16, 2026